(AIM: SAR)

20 December 2017

SAREUM HOLDINGS PLC

(“Sareum” or the “Company”)

Issue of Options

The Company announces that it granted on 19 December 2017 the following share options (the “Options”) to Dr Tim Mitchell, Chief Executive Officer, Dr John Reader, Chief Scientific Officer and Dr Stephen Parker, Non-Executive Chairman;

Drs Mitchell and Reader will each receive an option over 19,097,687 Shares, exercisable by no later than 19 December 2027 in the case of 9,548,844 Shares at 0.825 pence, 4,774,442 Shares at 1.2375 pence and 4,774,421 Shares at 1.65 pence per Share, respectively.

Dr Parker will receive an option over 6,545,455 Shares, exercisable by no later than 19 December 2027, in the case of 3,272,728 Shares at 0.825 pence, 1,636,364 Shares at 1.2375 pence and 1,636,363 Shares at 1.65 pence per Share, respectively.

Following the grants of Options referred to above, the interests of Directors in options over Shares will be as follows:

Director

Share scheme

Exercise price (pence)

No. of Shares under option

Percentage of issued share capital

Dr Tim Mitchell

EMI

       0.25

6,400,000

0.23%

 

EMI

       0.26

6,153,846

0.22%

 

EMI

       1.2

2,566,666

0.09%

 

EMI

       0.6

4,752,000

0.17%

 

EMI

       0.425

7,198,353

0.26%

 

EMI

       0.59

5,340,862

0.19%

 

EMI

       0.8

6,250,000

0.23%

 

EMI

       1.2

3,125,000

0.11%

 

EMI

       1.6

3,125,000

0.11%

 

Unapproved

       0.825

9,548,844

0.35%

 

Unapproved

       1.2375

4,774,422

0.17%

 

Unapproved

       1.65

4,774,421

0.17%

Dr John Reader

EMI

       0.25

6,400,000

0.23%

 

EMI

       0.26

6,153,846

0.22%

 

EMI

       1.2

2,566,666

0.09%

 

EMI

       0.6

4,752,000

0.17%

 

EMI

       0.425

7,198,353

0.26%

 

EMI

       0.59

5,340,862

0.19%

 

EMI

       0.8

6,250,000

0.23%

 

EMI

       1.2

3,125,000

0.11%

 

EMI

       1.6

3,125,000

0.11%

 

Unapproved

       0.825

9,548,844

0.35%

 

Unapproved

       1.2375

4,774,422

0.17%

 

Unapproved

       1.65

4,774,421

0.17%

Dr Stephen Parker

Unapproved

       0.8

5,000,000

0.18%

 

Unapproved

       1.2

2,500,000

0.09%

 

Unapproved

       1.6

2,500,000

0.09%

 

Unapproved

       0.825

3,272,728

0.12%

 

Unapproved

       1.2375

1,636,364

0.06%

 

Unapproved

       1.65

1,636,363

0.06%

 

For further information, please contact:

 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Co-Broker)

 

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

Shabnam Bashir/ Mark Swallow/ David Dible

020 7282 9571

Notes for editors: 

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company’s drug discovery technology platform (SKIL® - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

- Ends -

 

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… https://t.co/xq9zzVT44p via @Sareumplc
    View more